| Document |
Document Title |
|
WO/2020/083733A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoiso- mers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variablesare defined according to the description, (I) Th...
|
|
WO/2020/085504A1 |
A method for producing a compound represented by general formula (I) or a salt thereof by reacting a compound represented by general formula (II) or a salt thereof, with a diazotizing agent and hydrochloric acid, characterized by irradia...
|
|
WO/2020/086533A1 |
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2020/084094A1 |
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...
|
|
WO/2020/086732A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/079207A1 |
The present invention relates to processes of preparing N- ((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopro
pyl-1H- pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical composition...
|
|
WO/2020/079652A1 |
A DDR1 inhibitor compound can have a structure of Formula A, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center, ...
|
|
WO/2020/081381A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...
|
|
WO/2020/081856A1 |
A compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: Formula I wherein X1 is benzimidazolyl, substituted benzimidazolyl, azabenzimidazolyl, substituted azabenzimidazolyl, pyrazolyl, or substi...
|
|
WO/2020/080534A1 |
The present invention provides a method for controlling a plant disease by treating a plant or soil with a compound which has an excellent controlling effect on a plant disease and is represented by formula (I) [in the formula, Z represe...
|
|
WO/2020/079111A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2020/072797A1 |
Novel salts of niraparib are provided. Also provided are pharmaceutical compositions comprising those salts, as well as methods and uses pertaining to the same.
|
|
WO/2020/063407A1 |
The present invention relates to general formulas (I) and (II) an N-aromatic amide compound and a preparation method therefor, a pharmaceutical composition and a pharmaceutical preparation containing the general formulas (I) and (II), an...
|
|
WO/2020/065315A1 |
A composition comprising: a compound of formula (I): (I) wherein each of A, B, C and D are independently selected from: C1-18 alkyl; - CCl3; -CF3;C6-12 aryl optionally substituted with C1-18 alkoxy, -CN, -CF3, halogen, NO2, or C1-18 alky...
|
|
WO/2020/069065A1 |
The present disclosure relates to chemical moieties which, when bonded to pharmacophores, cause the pharmacophores to undergo first pass metabolism. By undergoing first pass metabolism, a pharmacophore may be made less bioavailable. Such...
|
|
WO/2020/065323A1 |
Provided is a process for preparing a compound, comprising the steps of a) Reacting a compound of Formula A (Formula A) with the compound 3 (3) to provide the compound 5 (5) or a salt or solvate thereof, wherein R is a linear or branched...
|
|
WO/2020/060092A1 |
The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of...
|
|
WO/2020/058945A1 |
The present invention is directed to methods of producing substituted pyrazole based compounds through novel intermediates and unique processes for preparing such intermediates which enables synthesis of final product through commerciall...
|
|
WO/2020/056090A1 |
Disclosed are compounds of Formulae 1 and 10 including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein E, L, J, A, T, R1, R2a, R2b, X, Y, R6a, R6b and R29 are as defined in the disclosure. Also disclosed ...
|
|
WO/2020/051344A1 |
This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant...
|
|
WO/2020/051402A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined in the disclosure. Also disclosed are compositions containing...
|
|
WO/2020/048471A1 |
Disclosed are a 7-substituted indazole derivative as shown in formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor, and the use of the same as a therapeutic agent, especially as aIRAK4 kinase inhib...
|
|
WO/2020/051260A1 |
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treatin...
|
|
WO/2020/043998A1 |
The present invention relates to a method for the sigmatropic rearrangement of a compound of formula (I) wherein R3 and R4 are as defined in the description, which consists in thermally treating said compound by microwaves.
|
|
WO/2020/046382A1 |
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utili...
|
|
WO/2020/041905A1 |
Provided are uses of and methods of treatment involving a sulfonamide for treatment of central nervous system trauma, including but not limited to a spinal cord injury and/or a traumatic brain injury. The central nervous system trauma ma...
|
|
WO/2020/040049A1 |
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-2.0 parts by mass with respect to 100 parts by...
|
|
WO/2020/038279A1 |
A substituted pyrazole compound represented by formula I, and a preparation method, a pharmaceutical composition, and use thereof. The compound has good stability, excellent solubility, small cell toxicity, and a significant effect on ne...
|
|
WO/2020/041562A1 |
This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the ...
|
|
WO/2020/039456A1 |
The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline for...
|
|
WO/2020/040048A1 |
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-0.2 parts by mass with respect to 100 parts by...
|
|
WO/2020/040050A1 |
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. The composition according to the present invention includes a compound (A) represent...
|
|
WO/2020/040045A1 |
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. This composition includes a compound (A) represented by general formula (1), and a c...
|
|
WO/2020/041100A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...
|
|
WO/2020/035464A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...
|
|
WO/2020/035540A1 |
Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced ...
|
|
WO/2020/025449A1 |
Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitab...
|
|
WO/2020/027225A1 |
One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivat...
|
|
WO/2020/027214A1 |
A method is provided which, by applying a compound represented by formula (1) or an N-oxide or agriculturally acceptable salt thereof, controls soybean rust fungus having an amino acid substitution of F129L in the mitochondrial cytochrom...
|
|
WO/2020/026259A1 |
Present invention provides novel Ethyl 2-bromo-4-[2-(3-halopyridin-2-yl)-hydrazinyl]-4-oxobutanoate
HBr salt, method of preparation and use thereof. The compound is prepared by reaction of ethyl (2Z)-4-[2-(3-chloropyridin-2-yl) hydrazin...
|
|
WO/2020/025444A1 |
Object of the present invention is a better crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D, stable, suitable for pharmaceutical purposes, and with the highest solubility in water and excellent non-hygroscopicit...
|
|
WO/2020/028723A1 |
The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a comp...
|
|
WO/2020/018975A1 |
The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activat...
|
|
WO/2020/011922A1 |
The present invention relates to certain dithiocarbamate compounds of formula (I) comprising a nitrogen containing heterocyclic ring, and exhibiting strong absorption in the visible range of the light spectrum. The compounds of the inven...
|
|
WO/2020/007273A1 |
Disclosed is a compound represented by formula (I) or a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate thereof. Also disclosed are a preparation method and use of the compound. The compound represented by formula (I)...
|
|
WO/2020/007704A1 |
The present invention relates to novel halogen-substituted compounds, to processes for their preparation and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids.
|
|
WO/2019/171234A9 |
The present invention relates to novel heterocyclic compound of Formula (I), (I) wherein, Het, L1, A, L2 and R12 are as defined in the detailed description, for use as fungicides.
|
|
WO/2020/010155A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/008317A1 |
The present invention is directed to acylsulfonamide derivatives of formula (I), pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of, for example, impaired oral glucose toler...
|
